Smart Drug Delivery Systems Market Poised for 17% Growth as Chronic Disease Management Evolves
• The global smart drug delivery systems market reached $12 billion in 2024 and is projected to grow at a CAGR of 17% through 2034, driven by rising chronic disease prevalence and technological advancements.
• Connected inhalers are gaining significant traction for respiratory and neurological conditions, with recent partnerships like Modivcare and Tenovi deploying Adherium's Hailie smart inhalers to improve patient care.
• Injectable smart delivery systems dominated the market with a $7.6 billion valuation in 2024, while North America leads regional adoption with $5.5 billion in revenue, expected to reach $22.2 billion by 2034.
Otulfi (Ustekinumab) Biosimilar Gains Regulatory Approvals in Canada and the UK for Inflammatory Diseases
• Health Canada approved Otulfi, a ustekinumab biosimilar, for subcutaneous and intravenous use in treating Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis.
• The UK's MHRA also approved Otulfi for the same indications, following approvals in the US and Europe, expanding treatment options for inflammatory diseases.
• Otulfi, developed by Formycon and commercialized by Fresenius Kabi, targets interleukin-12 and interleukin-23, offering a cost-effective alternative to Stelara.
• These approvals underscore the commitment to increasing access to biosimilars, potentially reducing healthcare costs and improving patient access to essential medicines.
© Copyright 2025. All Rights Reserved by MedPath